neupogen filgrastim (rbe) 300 microgram/1ml injection vial
amgen australia pty ltd - filgrastim, quantity: 300 microgram/ml - injection, solution - excipient ingredients: polysorbate 80; water for injections; sorbitol; acetate; sodium - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative of myelosuppressive therapy in patients with non-myeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications
neupogen filgrastim (rbe) 480 microgram/1.6ml injection vial
amgen australia pty ltd - filgrastim, quantity: 300 microgram/ml - injection, solution - excipient ingredients: acetate; sorbitol; water for injections; polysorbate 80; sodium - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs in doses not usually requiring bone marrow transplantation. for reducing the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative of myelosuppressive therapy in patients with non-myeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, for reducing the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications
neupogen 48 mu/1,6 ml solucion inyectable y para perfusion
amgen europe b.v. - filgrastim - excipientes: acetato sodico,polisorbato 80,sorbitol - inmunoestimulantes - factores estimulantes de colonias - filgrastim
neupogen 30 mu (0,3 mg/ml) solucion inyectable
amgen europe b.v. - filgrastim - soluciÓn inyectable y para perfusiÓn - 30 millones u - filgrastim 30 millones u - filgrastim
neupogen 30 mu (0,6 mg/ml) solucion inyectable en jeringa precargada
amgen europe b.v. - filgrastim - soluciÓn inyectable en jeringa precargada - 30 millones u - filgrastim 60 millones u - filgrastim
neupogen 48 mu (0,96 mg/ml) solucion inyectable en jeringa precargada
amgen europe b.v. - filgrastim - soluciÓn inyectable en jeringa precargada - 48 millones u - filgrastim 96 millones u - filgrastim
neupogen 300 mcg/ml (30 mln j.m./ml) roztwór do wstrzykiwań
amgen europe b.v. - filgrastimum - roztwór do wstrzykiwań - 300 mcg/ml (30 mln j.m./ml)
neupogen 600 mcg/ml (30 mln j.m./0,5 ml) roztwór do wstrzykiwań w ampułko-strzykawce
amgen europe b.v. - filgrastimum - roztwór do wstrzykiwań w ampułko-strzykawce - 600 mcg/ml (30 mln j.m./0,5 ml)
neupogen 960 mcg/ml (48 mln j.m./0,5 ml) roztwór do wstrzykiwań w ampułko-strzykawce
amgen europe b.v. - filgrastimum - roztwór do wstrzykiwań w ampułko-strzykawce - 960 mcg/ml (48 mln j.m./0,5 ml)
neupogen 48 48 m.u.i./0.5 ml solução injetável
amgen europe, b.v. - filgrastim - solução injetável - 48 m.u.i./0.5 ml - filgrastim 96 mu/ml - filgrastim - n/a - duração do tratamento: curta ou média duração